{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:13:35Z","timestamp":1791825215631,"version":"4.3.4"},"reference-count":27,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,11,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An important hallmark of cancer progression is the ability of tumor cells to evade immune recognition. Understanding the relationship between neoplastic cells and the immune microenvironment should facilitate the design of improved immunotherapies. Here we identify impaired T-cell immunologic synapse formation as an active immunosuppressive mechanism in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). We found a significant reduction in formation of the F-actin immune synapse in tumor-infiltrating T cells (P &lt; .01) from lymphoma patients compared with age-matched healthy donor cells. Peripheral blood T cells exhibited this defect only in patients with leukemic-phase disease. Moreover, we demonstrate that this T-cell defect is induced after short-term tumor cell contact. After 24-hour coculture with FL cells, previously healthy T cells showed suppressed recruitment of critical signaling proteins to the synapse. We further demonstrate repair of this defect after treatment of both FL cells and T cells with the immunomodulatory drug lenalidomide. Tissue microarray analysis identified reduced expression of the T-cell synapse signature proteins, including the cytolytic effector molecule Rab27A associated with poor prognosis, in addition to reduced T-cell numbers and activity with disease transformation. Our results highlight the importance of identifying biomarkers and immunotherapeutic treatments for repairing T-cell responses in lymphoma.<\/jats:p>","DOI":"10.1182\/blood-2009-04-217687","type":"journal-article","created":{"date-parts":[[2009,9,28]],"date-time":"2009-09-28T21:25:11Z","timestamp":1254173111000},"page":"4713-4720","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":225,"title":["Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy"],"prefix":"10.1182","volume":"114","author":[{"given":"Alan G.","family":"Ramsay","sequence":"first","affiliation":[{"name":"Institute of Cancer, Cancer Research UK Clinical Centre for Medical Oncology, Barts and The London School of Medicine, Queen Mary University of London, London;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Clear","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Cancer Research UK Clinical Centre for Medical Oncology, Barts and The London School of Medicine, Queen Mary University of London, London;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Kelly","sequence":"additional","affiliation":[{"name":"Bioinformatics and Biostatistics Service, Cancer Research UK, London; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rewas","family":"Fatah","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Cancer Research UK Clinical Centre for Medical Oncology, Barts and The London School of Medicine, Queen Mary University of London, London;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Matthews","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Cancer Research UK Clinical Centre for Medical Oncology, Barts and The London School of Medicine, Queen Mary University of London, London;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finlay","family":"MacDougall","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Cancer Research UK Clinical Centre for Medical Oncology, Barts and The London School of Medicine, Queen Mary University of London, London;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Andrew","family":"Lister","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Cancer Research UK Clinical Centre for Medical Oncology, Barts and The London School of Medicine, Queen Mary University of London, London;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail M.","family":"Lee","sequence":"additional","affiliation":[{"name":"Cellular Pathology, Barts and The London National Health Service Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Calaminici","sequence":"additional","affiliation":[{"name":"Cellular Pathology, Barts and The London National Health Service Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Cancer Research UK Clinical Centre for Medical Oncology, Barts and The London School of Medicine, Queen Mary University of London, London;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111721504644000_B1","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2006-10-041863","article-title":"How I treat indolent lymphoma.","volume":"109","author":"Gribben","year":"2007","journal-title":"Blood"},{"issue":"21","key":"2019111721504644000_B2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111721504644000_B3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.13574","article-title":"Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.","volume":"94","author":"de Jong","year":"2009","journal-title":"Haematologica"},{"issue":"26","key":"2019111721504644000_B4","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1200\/JCO.2005.06.004","article-title":"Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.","volume":"23","author":"Maloney","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111721504644000_B5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.hoc.2008.07.007","article-title":"Stem cell transplantation for non-Hodgkin's lymphoma.","volume":"22","author":"Wrench","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"2019111721504644000_B6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.cco.0000174040.52427.83","article-title":"Current status of therapeutic vaccines for non-Hodgkin's lymphoma.","volume":"17","author":"Hurvitz","year":"2005","journal-title":"Curr Opin Oncol"},{"issue":"15","key":"2019111721504644000_B7","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood-2008-07-170274","article-title":"T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.","volume":"113","author":"Houot","year":"2009","journal-title":"Blood"},{"issue":"16","key":"2019111721504644000_B8","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab.","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2019111721504644000_B9","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2008-12-172825","article-title":"Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB.","volume":"113","author":"Hagemann","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111721504644000_B10","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI31202","article-title":"Tregs and rethinking cancer immunotherapy.","volume":"117","author":"Curiel","year":"2007","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111721504644000_B11","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"30","key":"2019111721504644000_B12","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111721504644000_B13","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2004-02-0494","article-title":"Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells.","volume":"104","author":"Gricks","year":"2004","journal-title":"Blood"},{"issue":"13","key":"2019111721504644000_B14","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","article-title":"Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.","volume":"112","author":"Lapalombella","year":"2008","journal-title":"Blood"},{"issue":"31","key":"2019111721504644000_B15","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111721504644000_B16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2006.06439.x","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.","volume":"136","author":"Davies","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111721504644000_B17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.23881","article-title":"Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.","volume":"124","author":"Ai","year":"2009","journal-title":"Int J Cancer"},{"issue":"2","key":"2019111721504644000_B18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nri2021","article-title":"Regulation of T-cell activation by the cytoskeleton.","volume":"7","author":"Billadeau","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2019111721504644000_B19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood.V75.5.1154.1154","article-title":"T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone.","volume":"75","author":"Jacob","year":"1990","journal-title":"Blood"},{"issue":"11","key":"2019111721504644000_B20","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1182\/blood.V90.11.4297","article-title":"In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation.","volume":"90","author":"Dorfman","year":"1997","journal-title":"Blood"},{"issue":"9","key":"2019111721504644000_B21","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies.","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111721504644000_B22","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2019111721504644000_B23","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.","volume":"327","author":"Kwak","year":"1992","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111721504644000_B24","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat Med"},{"issue":"19","key":"2019111721504644000_B25","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2005.04.4289","article-title":"Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.","volume":"24","author":"Redfern","year":"2006","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111721504644000_B26","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1182\/blood-2009-01-201988","article-title":"Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma.","volume":"113","author":"Ai","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111721504644000_B27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2009-02-200543","article-title":"Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases.","volume":"114","author":"Xu","year":"2009","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/21\/4713\/1319095\/zh804709004713.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/21\/4713\/1319095\/zh804709004713.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T21:51:07Z","timestamp":1574027467000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/114\/21\/4713\/26405\/Follicular-lymphoma-cells-induce-Tcell-immunologic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,19]]},"references-count":27,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2009,11,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2009-04-217687","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,19]]}}}